Dianthus Therapeutics, Inc. /DE/ Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Dianthus Therapeutics, Inc. /DE/ (DNTH) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of $71.83 million as of 2023-09-11, per its 10-K filed 2025-03-11.
Financial Statements › Notes › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2025-03-11
- 2023-09-11: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $71.83M; Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net as first filed $71.59M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net as first filed |
|---|---|---|
| 2023-09-11 | $71.83M 10-K · filed 2025-03-11 | $71.59M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |